Pharmacokinetics and safety of tenofovir in hiv-infected women during labor and their infants during the first week of life

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 1, 2014, Pages 33-41

  Mirochnick, Mark ^a   Taha, Taha ^b   Kreitchmann, Regis ^c   Nielsen Saines, Karin ^d   Kumwenda, Newton ^b   Joao, Esau ^d   Pinto, Jorge ^e   Santos, Breno ^f   Parsons, Teresa ^g   Kearney, Brian ^h   Emel, Lynda ⁱ   Herron, Casey ⁱ   Richardson, Paul ^j   Hudelson, Sarah E ^j   Eshleman, Susan H ^j   George, Kathleen ^k,o   Fowler, Mary G ⁱ   Sato, Paul ^l,m   Mofenson, Lynne ^m,n  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Irmandade da Santa Casa de Misericordia de Porto Alegre   (Brazil)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF MALAWI   (Malawi)

^f Hospital Federal dos Servidores do Estado   (Brazil)

^g FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^h HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j GILEAD SCIENCES   (United States)

^k Fred Hutchinson Cancer Research Center   (United States)

^l FAMILY HEALTH INTERNATIONAL   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^o EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

more..

Author keywords

Neonate; Pharmacokinetics; Tenofovir

Indexed keywords

ALBUMIN; NEVIRAPINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AMNION FLUID; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BRAZIL; BREAST MILK; BRONCHOPNEUMONIA; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MILK LEVEL; DRUG SAFETY; FEMALE; GASTROENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOALBUMINEMIA; INFECTION PREVENTION; LABOR; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MARASMUS; MATERNAL BLOOD; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; NEWBORN; NEWBORN INFECTION; NEWBORN SEPSIS; OPEN STUDY; PERINATAL DRUG EXPOSURE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PREGNANT WOMAN; PRIORITY JOURNAL; RESPIRATORY FAILURE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; UMBILICAL CORD BLOOD;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FETAL BLOOD; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; LABOR, OBSTETRIC; ORGANOPHOSPHONATES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; YOUNG ADULT;

EID: 84893795240     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182a921eb     Document Type: Article

References (19)

1. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008; 22:973-981.
2. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
4. Van Rompay KK, Berardi CJ, Aguirre NL, et al. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS. 1998;12:F79-F83.
5. Van Rompay KK, Marthas ML, Lifson JD, et al. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses. 1998;14:761-773.
6. Tenofovir Prescribing Information. Foster City, CA: Gilead Sciences, Inc; 2012.
7. Hirt D, Urien S, Ekouevi DK, et al. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther. 2009;85:182-189.
8. Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother. 2011;55:5914-5922.
9. National Institutes of Health. Division of AIDS (DAIDS) revised toxicity tables for grading severity of pediatric adverse experiences. US National Institutes of Health DAIDS HIV Vaccine and Research Program, version 1.0. Washington, DC. 2004. Available at: http://rcc.tech-res-intl.com. Accessed April 02, 2012.
10. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004; 43:595-612.
11. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
12. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
13. Blum MR, Chittick GE, Begley JA, et al. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol. 2007;47: 751-759.
14. Ramanathan S, Shen G, Cheng A, et al. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr. 2007;45:274-279.
15. Foster C, Lyall H, Olmscheid B, et al. Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med. 2009;10:397-406.
16. Hirt D, Ekouevi DK, Pruvost A, et al. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2). Antimicrob Agents Chemother. 2011;55:2961-2967.
17. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167.
18. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52:3144-3160.
19. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297-3304.